The Neuphoria Therapeutics Inc. (NEUP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biotechnology company, Neuphoria uses its Forms 10-K, 10-Q and 8-K, along with proxy materials and other statements, to report on its business, pipeline, governance and material events.
For NEUP, current reports on Form 8-K are especially informative. Recent 8-K filings have described outcomes from the AFFIRM-1 Phase 3 trial of BNC210 in social anxiety disorder, the decision to discontinue further development of the SAD program, and the company’s plans for a full strategic review of its operations and portfolio. Other 8-Ks detail the adoption of a limited-duration stockholder rights plan, notices from The Nasdaq Stock Market LLC regarding listing rule compliance, and the holding of the company’s annual meeting of stockholders.
Neuphoria’s filings also include information on strategic and governance matters. A definitive proxy statement on Schedule 14A outlines proposals for director elections, auditor ratification, and advisory votes on executive compensation and its frequency. Additional 8-K disclosures describe changes in executive roles and the entry into a consulting agreement with the company’s former full-time CEO to serve as interim CEO during the strategic review and potential strategic transaction process.
Investors can use NEUP’s periodic reports, when available, to review financial statements, license revenue, research and development spending, and cash position, as well as risk factor discussions related to its CNS drug development programs and collaborations with partners such as Merck & Co., Inc. These documents also provide context on Neuphoria’s single operating segment focused on allosteric ion channel modulators.
On Stock Titan, NEUP filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain the key points in lengthy filings, highlight important clinical and strategic disclosures, and make it easier to locate information on topics such as trial outcomes, rights plans, annual meeting results, and material agreements. This allows users to quickly understand what each filing means for Neuphoria’s business and capital markets profile without reading every page in full.
Neuphoria Therapeutics Inc. (NEUP), through its Board of Directors, amended its Rights Agreement with Computershare Trust Company, N.A., as rights agent, extending the Final Expiration Date to the close of business on October 27, 2027, unless earlier extended, modified or terminated. The rights otherwise remain governed by the original agreement as amended.
Neuphoria Therapeutics Inc. (NEUP) shareholder AdvisorShares Trust reported beneficial ownership of 312,895 common shares, equal to 5.78% of the class. AdvisorShares Trust reported sole voting and dispositive power over all 312,895 shares, with zero shared voting power and zero shared dispositive power.
Neuphoria Therapeutics Inc. is asking stockholders to vote at its virtual-only 2026 Annual Meeting on November 2, 2026 at 9:00 a.m. Eastern Time on three items: re‑electing Alan Fisher as the Class II director, ratifying Wolf & Company P.C. as independent registered public accounting firm for the fiscal year ending June 30, 2027, and authorizing a potential adjournment of the meeting to solicit additional proxies if needed.
Stockholders of record at the close of business on September 10, 2026, when 5,411,334 shares of common stock were outstanding, are entitled to one vote per share. The proxy explains voting mechanics (including broker non‑votes, quorum at one‑third of outstanding shares, and telephone/Internet voting), the board’s committee structure and independence determinations, executive and director compensation (including a 2024 equity plan with a 1,000,000‑share reserve), principal stockholders such as Lynx1 Capital Management LP with 16.2% ownership, and related‑party arrangements including paid CFO services through Danforth Advisors and advisory work by WG Partners LLP. The document also notes that a separately called special meeting and separate proxy materials will address the proposed merger with Scancell Holdings plc.
Neuphoria Therapeutics Inc. (NEUP) is a clinical-stage biotechnology company that has radically downsized and is now primarily focused on completing a proposed merger with Scancell Holdings plc, preserving cash, and managing its partnered assets. After the Phase 3 AFFIRM-1 trial of BNC210 in social anxiety disorder failed to meet its primary and secondary endpoints in October 2025, Neuphoria discontinued the SAD program, terminated facility leases, reduced to one full-time employee, and paused almost all internal R&D, including the planned SYMPHONY Phase 2b/3 PTSD trial.
Under the July 23, 2026 Merger Agreement, Neuphoria is expected to become an indirect wholly owned subsidiary of Scancell. Each NEUP share would convert into Scancell American Depositary Shares plus one contingent value right (CVR), which entitles holders to a pro rata share of certain net proceeds, if any, from the Merck alpha7 PAM agreement, CTx CRC/Pfizer KAT6 arrangements, specified IP monetizations, and the Australian R&D tax credit as of June 30, 2026. Closing is subject to shareholder approvals, an effective Form F-4, Nasdaq listing of Scancell ADSs, Scancell raising at least $75.0 million in concurrent financing, and Neuphoria having at least $10.0 million of closing net cash.
Operations now center on preserving value in partnered programs—including Merck’s alpha7 PAMs (with up to $450.0 million in potential milestones plus tiered royalties), Pfizer’s Phase 3 KAT6 program via CTx CRC, and Carina Biotech’s CNA3103 CAR-T program—while maintaining limited clinical readiness for BNC210 in PTSD. The company recorded a $5.4 million goodwill impairment in fiscal 2026 and explicitly warns of substantial doubt about its ability to continue as a going concern if it cannot close the Scancell merger or raise sufficient additional capital.
Neuphoria Therapeutics Inc. shareholder group led by Coastlands Capital LP and Matthew D. Perry reports beneficial ownership of 228,594 shares of common stock. Based on 5,404,551 shares outstanding as of May 14, 2026, this represents 4.23% of the company’s common stock.
The reporting persons hold no sole voting or dispositive power, but have shared voting and shared dispositive power over all 228,594 shares. They state that the securities were not acquired to change or influence control of Neuphoria Therapeutics. This Amendment No. 1 is described as an exit filing, as the group no longer beneficially owns more than 5% of any class of the issuer’s securities.
Neuphoria Therapeutics Inc. agreed to an all‑share merger with UK-based Scancell Holdings plc, under which Neuphoria will become an indirect wholly owned subsidiary of Scancell. At closing, each Neuphoria common share will convert into Scancell American Depositary Shares based on a formulaic exchange ratio and one contingent value right (CVR).
Pre‑Merger Neuphoria stockholders (excluding PIPE subscribers) are expected to hold about 11.1% of the combined company on a fully diluted basis, compared with approximately 64.9% for existing Scancell shareholders and 17.3% for PIPE investors, using valuations of $144,612,002 for Scancell and $24,598,949 for Neuphoria. Completion is subject to multiple conditions, including stockholder and shareholder approvals, effectiveness of a Form F‑4 registration statement, Nasdaq listing of Scancell ADSs, Scancell receiving at least $75.0 million of concurrent financing proceeds, and Neuphoria having minimum Closing Net Cash of $10,000,000 as of December 31, 2026 or closing.
Each CVR will represent a contractual right to a pro rata share of 100% of net proceeds, if any, from specified Merck and Pfizer collaboration agreements, monetizations of certain Neuphoria intellectual property, and an Australian R&D tax credit for the year ended June 30, 2026. The broader transaction package includes a Scancell private placement expected to raise about $39.1 million, a planned $12.0 million UK placing, a retail offer of up to $3.0 million, and a non‑binding term sheet for up to $25 million in secured debt financing.
Neuphoria Therapeutics Inc. reported a small revenue distribution and outlined potential future income from its historical participation in the former Cancer Therapeutics Cooperative Research Centre (CTx CRC). On May 21, 2026, the company received a revenue distribution payment of AUD $1 tied to its licensing of the KAT6 program to Pfizer, following dosing of the first subject in the first Phase III trial in ER+/HER2- metastatic breast cancer.
Based on past program contributions, Neuphoria believes it is eligible to receive approximately 4.65% of any future milestone payments from CTXT, with total milestone value to all 17 partners estimated at USD $460M, though it cannot assess if or when such milestones will be achieved. The company also highlighted historical CTx CRC-related revenues, including AUD $967,583 in 2016 from an MSD agreement and AUD $1,416,026 in 2026 from licenses to Pfizer, contributing to cumulative CRC trust distributions of AUD $3,522,413.68 since 2016.
Neuphoria Therapeutics Inc. reported a small net loss of $0.5 million for the three months ended March 31, 2026, compared with net income of $11.3 million a year earlier, when it booked a large Merck milestone payment. There was no revenue this quarter.
Following the failure of its AFFIRM‑1 phase 3 trial in social anxiety disorder, the company has discontinued the BNC210 SAD program, paused the BNC210 PTSD program, terminated virtually all employees and exited its main facility, recording $1.3 million of restructuring costs over nine months.
Neuphoria raised $17.9 million net through equity sales, ending the period with cash and cash equivalents of $19.4 million and working capital of about $20.1 million. Management expects this to fund operations beyond the fourth quarter of fiscal 2027 and sees no substantial doubt about continuing as a going concern while it pursues strategic alternatives.
Neuphoria Therapeutics Inc. reported net income of $1.9 million for the quarter ended December 31 2025, driven largely by a $5.4 million gain on fair value adjustments to warrant and contingent consideration liabilities. This contrasts with a net loss of $1.9 million a year earlier.
For the six months ended December 31 2025, the company recorded a net loss of $8.0 million. Cash, cash equivalents and restricted cash rose to $22.3 million, supported by $17.9 million in equity financing, and management believes this will fund operations beyond the third quarter of fiscal 2027.
After a Phase 3 trial of BNC210 in social anxiety disorder failed its primary endpoint, Neuphoria discontinued that program, paused its PTSD program, terminated nearly all employees and exited its main facility, booking $1.2 million in restructuring costs. The company adopted a shareholder rights plan and is pursuing strategic alternatives, including potential mergers, acquisitions or other transactions, while maintaining partnerships such as its Merck collaboration.
Baselake Partners, LP, Baselake Management, LLC, and David Paolella have filed an amended Schedule 13G reporting a passive ownership stake in Neuphoria Therapeutics Inc. They report beneficial ownership of 222,222 shares of Neuphoria common stock, representing 4.1% of the outstanding class.
The filing states that the shares are held by Baselake Partners, LP, with Baselake Management, LLC as investment manager and Paolella as managing member. The reported ownership percentage is based on 5,377,329 shares outstanding as of November 13, 2025, and the group certifies the holdings are not for the purpose of changing or influencing control of the company.